SCHEMBL4397422

SCHEMBL4397422

CSc1nc(Cl)cc(Nc2nccs2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
GAA P10253 2/20 0.51
KDM4E B2RXH2 1/20 0.39
CSF1R P07333 1/20 0.37
LTK P29376 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
CDK7 P50613 1/20 0.37
CDK9 P50750 1/20 0.37
RPS6KA3 P51812 1/20 0.37
CDK5 Q00535 1/20 0.37
PTK2 Q05397 1/20 0.37
CAMK1D Q8IU85 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
ALK Q9UM73 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
AURKA O14965 2/20 0.36
AURKB Q96GD4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066542 0.81 KMT2A (0.40) KMT2AMEN1SMN1; SMN2GAAKDM4E
SCHEMBL4393863 0.81 RAB9A (0.39) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL10156743 0.72 MEN1 (0.63) KMT2AMEN1SMN1; SMN2GAAMAPK8
SCHEMBL5889134 0.72 NPC1 (0.43) KMT2AMEN1SMN1; SMN2GAACSF1R
SCHEMBL1532309 0.72 KDR (0.49) KMT2AMEN1SMN1; SMN2GAA
SCHEMBL341998 0.72 SMN1; SMN2 (0.40) KMT2AMEN1SMN1; SMN2GAAKDM4E
SCHEMBL2614898 0.71 KMT2A (0.57) KMT2AMEN1SMN1; SMN2GAAKDM4E
SCHEMBL2090416 0.70 MEN1 (0.73) KMT2AMEN1SMN1; SMN2GAAPTGES
SCHEMBL31073526 0.70 KMT2A (0.56) KMT2AMEN1SMN1; SMN2GAAKDM4E
SCHEMBL31073527 0.70 KMT2A (0.56) KMT2AMEN1SMN1; SMN2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306116-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY ASTRAZENECA AB (SE) 2009-12-10 US disclosed
EP-1931662-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY AstraZeneca AB (SE) 2008-06-18 EP disclosed
WO-2007031745-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY ASTRAZENECA AB (SE) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306116-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY IGF1R, IGFBP1, IRS1 KMT2A 3928/4885MEN1 2175/4885SMN1; SMN2 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.